Claims
- 1. A method of removing retained mucus secretions from the lungs of a human subject in need of such treatment, consisting essentially of:
- generating an aerosol suspension of respirable solid, dry particulate amiloride, wherein said solid particulate amiloride is comprised of particles of about 1 to 5 microns, wherein said aerosol suspension is free of liquid amiloride particles; and then
- delivering by inhalation said aerosol suspension of respirable solid particulate amiloride to the respiratory system of said subject in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of said subject of from about 10.sup.-7 to 10.sup.-3 Moles/liter, wherein the daily dose of said solid particulate amiloride is from about 1 to about 20 milligrams, and wherein said solid particulate amiloride is comprised of particles of about 1 to 5 microns, and whereby said secretions are hydrated and transported from the lung via mucociliary action.
- 2. A method according to claim 1, wherein said solid particulate amiloride is administered to the respiratory system of said subject in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of said subject of from 10.sup.-6 to about 10.sup.-4 moles/liter.
- 3. A method according to claim 1, wherein said aerosol consists essentially of particles of amiloride having a particle size within the range of about 1 to 5 microns.
- 4. A method according to claim 1, wherein said solid particulate amiloride comprises a pharmaceutically acceptable salt of amiloride.
- 5. A method according to claim 1, wherein said solid particulate amiloride comprises a free base of amiloride.
- 6. A method according to claim 1, wherein said solid particulate amiloride comprises a mixture of a free base of amiloride and a pharmaceutically acceptable salt of amiloride.
- 7. A method according to claim 1, wherein said solid particulate amiloride further comprises a dispersant.
- 8. A method according to claim 7, wherein said dispersant comprises lactose.
- 9. A method of treating cystic fibrosis in a human subject in need of such treatment, consisting essentially of:
- generating an aerosol suspension of respirable solid, dry particulate amiloride, wherein said solid particulate amiloride is comprised of particles of about 1 to 5 microns, and wherein said aerosol suspension is free of liquid amiloride particles; and then
- delivering by inhalation said aerosol suspension of respirable solid particulate amiloride to the respiratory system of said subject in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of said subject of from about 10.sup.-7 to 10.sup.-3 Moles/liter, wherein the daily dose of said solid particulate amiloride is from about 1 to about 20 milligrams, and wherein said solid particulate amiloride is comprised of particles of between about 1 to 5 microns, whereby mucus secretions in the lungs of said subject are hydrated and transported from the lung via mucociliary action.
- 10. A method according to claim 9, wherein said aerosol consists essentially of particles of amiloride having a particle size within the range of about 1 to 5 microns.
- 11. A method according to claim 9, wherein said solid particulate amiloride is administered to the respiratory system of said subject in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of said subject of from 10.sup.-6 to about 10.sup.-4 moles/liter.
- 12. A method according to claim 9, wherein said solid particulate amiloride comprises a mixture of a free base of amiloride and a pharmaceutically acceptable salt of amiloride.
- 13. A method according to claim 9, wherein said solid particulate amiloride comprises a free base of amiloride.
- 14. A method according to claim 9, wherein said solid particulate amiloride comprises a mixture of a free base of amiloride and a pharmaceutically acceptable salt of amiloride.
- 15. A method according to claim 9, wherein said solid particulate amiloride further comprises a dispersant.
- 16. A method according to claim 15, wherein said dispersant comprises lactose.
Parent Case Info
This is a continuation of application Ser. No. 08/218,839 filed Mar. 28, 1994, which is a File Wrapper Continuation of application Ser. No. 07/908,579 filed Jun. 29, 1992, which is a File Wrapper Continuation of application Ser. No. 07/593,193 filed Oct. 5, 1990 all abandoned.
Government Interests
This invention was made with Government support under Grant No. HL34322, awarded by the National Institutes of Health. The Government has certain rights in the invention.
US Referenced Citations (5)
Non-Patent Literature Citations (2)
Entry |
I.M. Bowler, Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial, Archives of Disease in Childhood 73, 427-30 (1995). |
M. Knowles et al., New Eng. J. Med. 322, No. 17, 1189-1194 (1990). |
Continuations (3)
|
Number |
Date |
Country |
Parent |
218839 |
Mar 1994 |
|
Parent |
908579 |
Jun 1992 |
|
Parent |
593193 |
Oct 1990 |
|